Abeona Therapeutics Inc. (ABEO)

Abeona Therapeutics Inc. (ABEO) Healthcare & Pipeline Overview

Abeona Therapeutics Inc. pioneers gene and cell therapies for rare genetic diseases, with a focus on recessive dystrophic epidermolysis bullosa (RDEB) and Sanfilippo syndrome. Their clinical-stage pipeline and AIM vector platform position them in the competitive biotechnology landscape, targeting unmet needs in life-threatening conditions.

What Is the Investment Thesis for ABEO?

Abeona Therapeutics presents a high-risk, high-reward investment opportunity centered on its innovative gene and cell therapy pipeline targeting rare genetic diseases. The primary value driver is the potential approval and commercialization of EB-101 for RDEB, currently in Phase III trials. Positive clinical data and regulatory milestones could significantly increase the company's valuation. However, the company's profitability is uncertain, with a negative free cash flow of $-0.04B. The company's high profit margin of 1223.1% is misleading due to the nature of biotech accounting and R&D spending. Upcoming data readouts from other pipeline programs, such as ABO-102 for Sanfilippo syndrome type A, represent potential catalysts. The company's success hinges on navigating regulatory hurdles, securing funding for ongoing clinical trials, and demonstrating the long-term efficacy and safety of its therapies.

Based on FMP financials and quantitative analysis

ABEO Key Highlights

• Market capitalization of $362.77M reflects investor sentiment regarding the potential of Abeona's gene and cell therapy pipeline.
• Phase III clinical trial for EB-101, a gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), represents a critical milestone.
• Profit margin of 1223.1% is atypical for a clinical-stage biotech company and should be interpreted with caution, reflecting specific accounting treatments and R&D investments.
• Negative free cash flow of $-0.04B indicates the company's reliance on external funding to support its research and development activities.
• Beta of 1.19 suggests that the stock is more volatile than the market average.

Who Are ABEO's Competitors?

ABEO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ABEO's Key Strengths?

• Advanced clinical-stage pipeline with EB-101 in Phase III trials.
• Proprietary AIM vector platform for gene therapy delivery.
• Focus on rare genetic diseases with high unmet medical needs.
• Experienced management team with expertise in gene and cell therapy.

What Are ABEO's Weaknesses?

• Limited financial resources and reliance on external funding.
• High risk associated with clinical-stage drug development.
• Competition from larger pharmaceutical companies in the gene therapy space.
• Regulatory hurdles and potential delays in approval process.

What Could Drive ABEO Stock Higher?

• Data readouts from Phase III clinical trial of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB).
• Progress updates on ABO-102 for Sanfilippo syndrome type A.
• Advancement of ABO-401 for cystic fibrosis through preclinical and clinical development.
• Potential strategic partnerships and collaborations to accelerate pipeline development.

What Are the Key Risks for ABEO?

• Financial-distress signal — its Altman Z-Score of 0.88 sits in the distress zone (elevated bankruptcy risk).
• Insider selling — insiders were net sellers of roughly $1.5M recently.
• Clinical trial failures or setbacks for key pipeline programs.
• Regulatory delays or disapproval of gene therapy products.
• Competition from other companies developing gene and cell therapies.
• Dependence on external funding to support research and development activities.
• Adverse events or safety concerns associated with gene therapy products.

What Are the Growth Opportunities for ABEO?

• Expansion of EB-101 into additional indications: While EB-101 is currently focused on RDEB, there is potential to expand its application to other blistering skin conditions with similar genetic mutations. This could significantly broaden the addressable market and extend the product's lifecycle. The market size for related blistering diseases is estimated to be substantial, with ongoing research exploring the underlying genetic causes. This expansion could be pursued within the next 3-5 years, contingent on further clinical research and regulatory approvals.
• Advancement of ABO-102 for Sanfilippo syndrome type A: ABO-102, Abeona's AAV-based gene therapy for Sanfilippo syndrome type A, represents a significant growth opportunity. Sanfilippo syndrome is a rare and devastating neurodegenerative disease with limited treatment options. Positive clinical data and regulatory approval could lead to substantial revenue generation. The market for Sanfilippo syndrome therapies is estimated to be significant, given the high unmet need and the potential for disease-modifying treatments. This program is expected to advance through clinical trials over the next 2-4 years.
• Development of ABO-401 for cystic fibrosis: Abeona's ABO-401 program targets cystic fibrosis, a genetic disorder affecting the lungs and other organs. While the cystic fibrosis market is competitive, there remains a need for more effective and durable therapies. ABO-401 leverages Abeona's AIM vector platform to deliver gene therapy to the lungs. The cystic fibrosis market is substantial, with ongoing research focused on gene editing and personalized medicine approaches. This program is in earlier stages of development, with potential clinical trials in the next 3-5 years.
• Leveraging the AIM vector platform: Abeona's AIM vector platform is a key asset that can be leveraged to develop gene therapies for a wide range of genetic diseases. The platform is designed to improve the delivery and efficacy of gene therapies, potentially leading to better clinical outcomes. The market for gene therapy vectors is growing rapidly, driven by increasing demand for efficient and safe delivery systems. Abeona can explore partnerships and collaborations to expand the application of its AIM vector platform to other therapeutic areas. This platform can be utilized for multiple programs over the next 5-10 years.
• Strategic partnerships and collaborations: Abeona can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its gene and cell therapies. These partnerships can provide access to funding, expertise, and infrastructure, enabling Abeona to expand its reach and impact. The biotechnology industry is characterized by collaborations between smaller biotech firms and larger pharmaceutical companies. Abeona can actively seek out partnerships to advance its pipeline and bring its therapies to market more effectively. These partnerships can be established in the next 1-3 years.

What Opportunities Does ABEO Have?

• Expansion of EB-101 into additional indications.
• Advancement of ABO-102 for Sanfilippo syndrome type A.
• Strategic partnerships and collaborations with larger pharmaceutical companies.
• Leveraging the AIM vector platform for new gene therapy programs.

What Threats Does ABEO Face?

• Clinical trial failures and setbacks.
• Regulatory disapproval of key pipeline programs.
• Competition from new and emerging gene therapy technologies.
• Difficulty in recruiting patients for rare disease clinical trials.

What Are ABEO's Competitive Advantages?

• Proprietary gene and cell therapy technologies.
• Focus on rare genetic diseases with limited competition.
• Advanced clinical-stage pipeline with potential for first-in-class therapies.
• Expertise in gene therapy vector development and manufacturing.
• Strong intellectual property portfolio protecting its technologies and therapies.

What Does ABEO Do?

Abeona Therapeutics Inc., founded in 1974 and formerly known as PlasmaTech Biopharmaceuticals, Inc., is a clinical-stage biopharmaceutical company dedicated to developing innovative gene and cell therapies for life-threatening rare genetic diseases. The company's lead program, EB-101, is an autologous, gene-corrected cell therapy currently in Phase III clinical trials for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a devastating skin blistering condition. Beyond EB-101, Abeona is advancing a pipeline of adeno-associated virus (AAV)-based gene therapies, including ABO-102 for Sanfilippo syndrome type A (MPS IIIA), ABO-201 for CLN3 disease, ABO-401 for cystic fibrosis, and ABO-50X for genetic eye disorders. These therapies leverage the company's AIM vector platform, which is designed to improve the delivery and efficacy of gene therapies. Abeona's strategic focus on rare diseases reflects a commitment to addressing unmet medical needs and developing potentially transformative treatments for patients with limited therapeutic options. The company operates with a team of 136 employees and is headquartered in Cleveland, Ohio, with research and development activities centered on advancing its gene and cell therapy programs through clinical trials and regulatory approval.

What Products and Services Does ABEO Offer?

• Develop gene therapies for rare genetic diseases.
• Focus on life-threatening conditions with limited treatment options.
• Utilize gene-corrected cell therapies and AAV-based gene therapies.
• Advance clinical trials for EB-101 in recessive dystrophic epidermolysis bullosa (RDEB).
• Develop ABO-102 for Sanfilippo syndrome type A.
• Create ABO-201 to treat CLN3 disease.
• Develop ABO-401 for the treatment of cystic fibrosis.
• Create ABO-50X for the treatment of genetic eye disorders.

How Does ABEO Make Money?

• Develop and commercialize gene and cell therapies for rare genetic diseases.
• Generate revenue through licensing agreements and potential product sales.
• Focus on research and development to advance pipeline programs through clinical trials.
• Seek strategic partnerships and collaborations to accelerate development and commercialization.

What Industry Does ABEO Operate In?

Abeona Therapeutics operates within the rapidly evolving biotechnology industry, specifically in the gene and cell therapy space. This sector is characterized by high growth potential, driven by advancements in genetic engineering and a growing understanding of disease mechanisms. The competitive landscape includes established pharmaceutical companies and smaller biotech firms, all vying to develop innovative therapies for unmet medical needs. The market for gene and cell therapies is projected to reach billions of dollars in the coming years, fueled by increasing regulatory approvals and the potential for curative treatments. Abeona's focus on rare genetic diseases positions it within a niche market with limited competition, but also presents challenges in terms of patient recruitment and market access.

Who Are ABEO's Key Customers?

• Patients with rare genetic diseases, such as recessive dystrophic epidermolysis bullosa (RDEB) and Sanfilippo syndrome type A.
• Healthcare providers who treat patients with these conditions.
• Hospitals and medical centers that specialize in gene and cell therapy.
• Pharmaceutical companies through licensing and collaboration agreements.

Abeona Therapeutics Inc. Financial Trajectory

Abeona Therapeutics Inc. (ABEO) reported $8.7M in revenue for Q1 2026, reflecting 60.9% growth compared to the prior quarter. The company recorded a net loss of $17.1M, with diluted EPS of $-0.30. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company.

Company Profile

Abeona Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cleveland, US. The company is led by CEO Vishwas Seshadri. ABEO has traded publicly since 1980.

How Abeona Therapeutics Inc. Is Valued

Abeona Therapeutics Inc. carries a market capitalization of $362.77M, placing it in the small-cap category. Relative to its peer group, ABEO's quantitative score of 36/100 is below the peer average of 67/100.

ROE 71%Key Financial Metrics

Return on equity for Abeona Therapeutics Inc. stands at 71.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -38.9%, showing how much profit it generates from its asset base. ABEO trades at a trailing price-to-earnings ratio of 20.16, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.89 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 6/9Financial Health

Abeona Therapeutics Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.88 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Abeona Therapeutics Inc. revenue of about $66.3M for fiscal 2026, with EPS near $-0.72. The estimate reflects 5 contributing analysts.

Net sellingInsider Activity

Over the past six months, Abeona Therapeutics Inc. insiders filed 29 SEC Form 4 transactions — 22 sales and 7 purchases. On net that is roughly 29K shares disposed (about $1.5M), a signal worth weighing alongside the fundamentals.

ABEO Financials

ABEO Latest News

ABEO Analyst Consensus

ABEO MoonshotScore

Latest Abeona Therapeutics Inc. Analysis

What Investors Ask About Abeona Therapeutics Inc. (ABEO) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources